epoprostenol

(redirected from Veletri)

epoprostenol

 [e″po-pros´tĕ-nol]
name for prostacyclin when used pharmaceutically; it is used in the form of the sodium salt as an inhibitor of platelet aggregation for blood contacting nonbiological systems, as in renal dialysis, as a pulmonary antihypertensive, and as a vasodilator.

pros·ta·cy·clin

(pros'tă-sī'klin),
A potent natural inhibitor of platelet aggregation and a powerful vasodilator.

epoprostenol

/ep·o·pro·sten·ol/ (e″po-pros´tĕ-nol) name for prostacyclin when used pharmaceutically; used in the form of the sodium salt as an inhibitor of platelet aggregation when blood contacts nonbiological systems, a pulmonary antihypertensive, and a vasodilator.

epoprostenol

[e′popros′tĕnol]
name for prostacyclin when used pharmaceutically. It is used in the form of the sodium salt as an inhibitor of platelet aggregation for blood contacting nonbiological systems, as in renal dialysis; as a pulmonary antihypertensive; and as a vasodilator.

Beraprost

An oral prostacyclin PGI2 analogue with vasodilator, antiplatelet, and cytoprotective effects, used to manage pulmonary arterial hypertension. Beraprost improves exercise capacity and symptoms in NYHA-functional class-II and -III patients with PAH and, in particular, in those with primary pulmonary hypertension.

Adverse effects
Headache, facial flushing, vasodilation.

epoprostenol

Prostacyclin. A powerful inhibitor of clumping of blood platelets and thus of blood clotting. It is used with heart-lung (cardiopulmonary bypass) machines and artificial kidneys (dialysis machines) to preserve the platelets in the blood being pumped through them. Epoprostenol also widens (dilates) arteries. A brand name is Flotan.

epoprostenol

References in periodicals archive ?
Actelion Acquisition: The acquisition gives JNJ five currently-marketed therapies (Opsumit, Tracleer, Uptravi, Veletri and Ventavis) for the treatment of pulmonary hypertension and two currently-marketed specialty products, Valchlor gel (cutaneous T-cell lymphoma) and Zavesca (Gaucher disease in the U.
Actelion is a highly profitable life science firm as a result of our leading franchise in pulmonary arterial hypertension (PAH), where our three marketed products Tracleer, Ventavis and Veletri continue to bring significant value to patients.
M2 PHARMA-August 27, 2010-Actelion says FDA OKs brand name VELETRI for epoprostenol for injection therapy(C)2010 M2 COMMUNICATIONS
27 August 2010 - Actelion Pharmaceuticals US Inc, part of Swiss Actelion Ltd (VTX: ATLN), said on Wednesday that the US Food and Drug Administration (FDA) has approved the brand name VELETRI for the company's epoprostenol for injection therapy.
19) The Italian military scenes in Don Alvaro o la fuerza del sino take place in Veletri, near the place where in 1744 Austrian Imperial forces were defeated by Spanish and Neapolitan troops led by Carlos de Borbon, King of Naples.
announced the second pivotal Phase III clinical trial of Veletri -- an intravenous dual endothelin receptor antagonist -- did not meet its primary objective of significantly improving symptoms (dyspnea, or shortness of breath) associated with acute heart failure.
The various drugs used to treat PAH are: Tracleer (bosentan), Letairis (ambrisentan), Remodulin (treprostinil), Ventavis (iloprost), Revatio (sildenafil), Adcirca (tadalafil), Tyvaso (inhaled treprostinil), and Veletri (epoprostenol).
GlobalData's pharmaceuticals report, Veletri (epoprostenol) - Analysis and Forecasts from 2010 to 2020 provides Veletri sales estimates for US, EU5 and Japan.
Tracleer, which was the second-to-launch agent for PAH in the United States (2001) after epoprostenol (GlaxoSmithKline/Gilead's Flolan, Actelion's Veletri, generics), has been used in the treatment of PAH for almost a decade and is regarded by many physicians as offering the best balance between documented efficacy, safety and tolerability, and delivery in the majority of PAH patients.
endothelin receptor antagonist Veletri in acute heart failure
In the RITZ-2 trial, Veletri demonstrated statistically significant hemodynamic (blood circulation) benefits in its primary efficacy measure, improvement in cardiac index (CI, the amount of blood pumped by the heart per minute/body surface area).
Tracleer(TM) and Veletri, its two flagship drugs, are in late stage development for several cardiovascular disorders, including chronic and acute heart failure as well as pulmonary arterial hypertension.